Optimizing metastatic-cascade-dependent Rac1 targeting in breast cancer: Guidance using optical window intravital FRET imaging.

A Floerchinger, Murphy KJ, Latham SL, Warren SC, McCulloch AT, Lee YK, J Stoehr, P Mélénec, Guaman CS, Metcalf XL, V Lee, A Zaratzian, Silva A Da, M Tayao, S Rolo, M Phimmachanh, G Sultani, L McDonald, Mason SM, N FerrariOoms LM, Johnsson AE, Spence HJ, Olson MF, Machesky LM, Sansom OJ, Morton JP, Mitchell CA, Samuel MS, Croucher DR, Welch HCE, K Blyth, Caldon CE, D Herrmann, Anderson KI, P Timpson, M Nobis

Research output: Contribution to journalArticlepeer-review

Abstract

Assessing drug response within live native tissue provides increased fidelity with regards to optimizing efficacy while minimizing off-target effects. Here, using longitudinal intravital imaging of a Rac1-Förster resonance energy transfer (FRET) biosensor mouse coupled with in vivo photoswitching to track intratumoral movement, we help guide treatment scheduling in a live breast cancer setting to impair metastatic progression. We uncover altered Rac1 activity at the center versus invasive border of tumors and demonstrate enhanced Rac1 activity of cells in close proximity to live tumor vasculature using optical window imaging. We further reveal that Rac1 inhibition can enhance tumor cell vulnerability to fluid-flow-induced shear stress and therefore improves overall anti-metastatic response to therapy during transit to secondary sites such as the lung. Collectively, this study demonstrates the utility of single-cell intravital imaging in vivo to demonstrate that Rac1 inhibition can reduce tumor progression and metastases in an autochthonous setting to improve overall survival.
Original languageEnglish
JournalCell Reports
DOIs
Publication statusPublished - 1 Sept 2021

Fingerprint

Dive into the research topics of 'Optimizing metastatic-cascade-dependent Rac1 targeting in breast cancer: Guidance using optical window intravital FRET imaging.'. Together they form a unique fingerprint.

Cite this